Evidence map›Paper›PMID 37153614›Full record

ArticleFrontiers in immunology2023

Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus.

María García-González, Fuensanta Gómez-Bernal, Juan C Quevedo-Abeledo, Yolanda Fernández-Cladera, Agustín F González-Rivero, Antonia de Vera-González, Iñigo de la Rua-Figueroa, Raquel López-Mejias, Federico Díaz-González, Miguel Á González-Gay and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

María García-GonzálezDivision of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
Fuensanta Gómez-BernalDivision of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
Juan C Quevedo-AbeledoDivision of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain.
Yolanda Fernández-CladeraDivision of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
Agustín F González-RiveroDivision of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
Antonia de Vera-GonzálezDivision of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
Iñigo de la Rua-FigueroaDivision of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain.
Raquel López-MejiasEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación sanitaria Marqués de Valdecilla (IDIVAL), Santander, Spain.
Federico Díaz-GonzálezDivision of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
Miguel Á González-GayDivision of Rheumatology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
Iván Ferraz-AmaroDivision of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
Hospital Universitario de Canarias · ESHospital Universitario de Gran Canaria Doctor Negrín · ESInstituto de Investigación Marqués de Valdecilla · ESUniversidad de La Laguna · ESUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To date a complete characterization of the components of the complement (C) pathways (CLassical, LEctin and ALternative) in patients with systemic lupus erythematosus (SLE) has not been performed. We aimed to assess the function of these three C cascades through functional assays and the measurement of individual C proteins. We then studied how they relate to clinical characteristics. Methods: New generation functional assays of the three pathways of the C system were assessed in 284 patients with SLE. Linear regression analysis was performed to study the relationship between the activity, severity, and damage of the disease and C system. Results: Lower values of the functional tests AL and LE were more frequent than those of the CL pathway. Clinical activity was not related to inferior values of C routes functional assays. The presence of increased DNA binding was negatively linked to all three C pathways and products, except for C1-inh and C3a which were positively related. Disease damage revealed a consistent positive, rather than a negative, relationship with pathways and C elements. Anti-ribosomes and anti-nucleosomes were the autoantibodies that showed a greater relationship with C activation, mainly due to the LE and CL pathways. Regarding antiphospholipid antibodies, the most related with C activation were IgG anti-β2GP, predominantly involving the AL pathway. Conclusion: Not only the CL route, but also the AL and LE are related to SLE features. C expression patterns are linked to disease profiles. While accrual damage was associated with higher functional tests of C pathways, anti-DNA, anti-ribosomes and anti-nucleosomes antibodies, were the ones that showed a higher relationship with C activation, mainly due to the LE and CL pathways.

Indexed as

Lupus Erythematosus, SystemicAntibodies, AntinuclearAntibodies, AntiphospholipidAutoantibodiesComplement System ProteinsHumansAntibodies, AntinuclearAntibodies, AntiphospholipidAutoantibodiesComplement System Proteinscomplement pathwayscomplement systemdisease activitydisease damagedisease profilessystemic lupus erythematosus

Identifiers

PMID37153614
PMCPMC10160460
OpenAlexW4366770892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.